← All Vertex Pharmaceuticals INC / Ma filings

Vertex Pharmaceuticals INC / Ma DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
DEF: Vertex Pharmaceuticals 2026 Proxy Statement Summary
Vertex Pharmaceuticals' 2026 proxy statement highlights strong 2025 financial performance, pipeline progress, and executive compensation alignment.
NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
DEFA14A: Vertex Pharmaceuticals Files Definitive Proxy Statement
Vertex Pharmaceuticals has filed a definitive proxy statement with the SEC.
NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
DEF: Vertex Pharmaceuticals Reports Strong 2024 Performance, Diversifies Pipeline
Vertex Pharmaceuticals achieved significant growth in 2024, driven by commercial success, R&D advancements, and strategic business development, setting the stage for continued value creation.
NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
DEFA14A: Vertex Pharmaceuticals Inc. Files Definitive Proxy Statement
Vertex Pharmaceuticals Incorporated files a definitive proxy statement with the SEC.
NASDAQ
VRTX
Vertex Pharmaceuticals INC / Ma
DEF 14A: Vertex Pharmaceuticals Reports Transformative 2023, Eyes Expansion Beyond Cystic Fibrosis
Vertex Pharmaceuticals highlights a transformative year in 2023, marked by growth in cystic fibrosis (CF) treatments, commercial diversification with CASGEVY, and advancements in its pipeline.